105 related articles for article (PubMed ID: 22186071)
1. [How to optimize the carrying out and the development of post-registration studies].
Borel T; Jouan-Flahault C;
Therapie; 2011; 66(6):469-72. PubMed ID: 22186071
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing strategies for medicines.
Breckenridge A
Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
[No Abstract] [Full Text] [Related]
3. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
Avouac B
Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
[TBL] [Abstract][Full Text] [Related]
5. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
6. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
7. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
8. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. The marketplace can't give us the drug safety data we need.
Avorn J
MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
[No Abstract] [Full Text] [Related]
11. Potential role of postmarketing research.
Venulet J
Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
[TBL] [Abstract][Full Text] [Related]
12. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
13. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
14. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
15. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
16. The unfinished business of U.S. drug safety regulation.
Evans BJ; Flockhart DA
Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
[No Abstract] [Full Text] [Related]
17. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
Xie Y; Tian F
Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing observational studies: my experience in the drug industry.
BMJ; 2012 Jun; 344():e3990. PubMed ID: 22692654
[No Abstract] [Full Text] [Related]
19. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
20. European biologicals registers: methodology, selected results and perspectives.
Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
